FDA Approves Purdue Pharma's Abuse-Deterrent Oxycodone

FDA Wednesday (July 23) approved Purdue Pharma's abuse-deterrent, extended-release oxycodone with labeling consistent with the agency's 2013 draft guidance on abuse-deterrent labeling and evaluation, the agency said. Targeniq ER's abuse deterrence stems from the inclusion of naloxone, a medication used to reverse the effects of opioid overdose and that blocks the euphoric effects of oxycodone. Targeniq is the second ER/LA opioid with FDA-approved labeling consistent with a draft guidance issued by the agency last year on ER/LA opioid labeling. The...